TISSUE-SPECIFIC TRANSCRIPTION OF DNA SEQUENCE ENCODING A HETEROLOGOUS ENZYME FOR USE IN PRODRUG THERAPY TO LUNG CANCER

摘要

The invention relates to the use of a molecular chimaera with a prodrug in the therapy of lung cancer, the molecular chimaera comprising a transcriptional regulatory DNA sequence derived from a gene encoding a lung-associated protein or a neuroendocrine marker protein and, operatively linked to the transcriptional regulatory DNA sequence, DNA sequence encoding a heterologous enzyme capable of catalysing the conversion of the prodrug into an agent toxic to a lung cancer cell. The use of lung specific promoters in a GDEPT or VDEPT approach allows specific targetting of lung cancer cells.